Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $179.00 at JPMorgan Chase & Co.

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $179.00 at JPMorgan Chase & Co.

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target raised by JPMorgan Chase & Co. from $171.00 to $179.00 in a report issued on Monday,Benzinga reports. The firm currently has an overweight rating on the stock. A number of other research firms have also recently weighed in on NBIX. The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a “buy” rating and a …